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Abstract: In spite of major advances in oncology, the World Health Organization predicts that cancer incidence will 
double within the next two decades. Although it is well understood that cancer is a hyperproliferative disorder medi-
ated through dysregulation of multiple cell signaling pathways, most cancer drug development remains focused on 
modulation of specific targets, mostly one at a time, with agents referred to as “targeted therapies,” “smart drugs,” 
or “magic bullets.” How many cancer targets there are is not known, and how many targets must be attacked to con-
trol cancer growth is not well understood. Although more than 90% of cancer-linked deaths are due to metastasis 
of the tumor to vital organs, most drug targeting is focused on killing the primary tumor. Besides lacking specificity, 
the targeted drugs induce toxicity and side effects that sometimes are greater problems than the disease itself. 
Furthermore, the cost of some of these drugs is so high that most people cannot afford them. The present report 
describes the potential anticancer properties of curcumin, a component of the Indian spice turmeric (Curcuma 
longa), known for its safety and low cost. Curcumin can selectively modulate multiple cell signaling pathways linked 
to inflammation and to survival, growth, invasion, angiogenesis, and metastasis of cancer cells. More clinical trials 
of curcumin are needed to prove its usefulness in the cancer setting. 
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Introduction 
Cancer is a group of over 200 neoplastic dis-
eases, all of which are caused by the dysregula-
tion of multiple cell signaling pathways [1]. A 
cancer may have as many as 500 different dys-
regulated genes. The dysregulation of various 
genes may occur over a period as long as 20-30 
years before a given cancer begins to manifest 
its symptoms. Therefore, targeting or inhibiting 
a single gene product or cell signaling pathway 
is unlikely to prevent or destroy cancer. 
Chemotherapy and specific targeted drugs 
have been developed to disrupt these gene 
products or pathways, thereby inducing cell 
death and impeding progression of malignant 
changes in cells. However, problems such as 
ineffective targeting and drug resistance have 
plagued these agents, necessitating changes 
in the approach to systemic cancer therapy. 
The current paradigm of cancer chemotherapy 
is either combinations of several drugs or a 
drug that modulates multiple targets. The com-
bination chemotherapy approach uses drugs 
with different mechanisms of action to increase 
cancer killing [2]. Various drugs that modulate 
multiple targets, have been approved by the 
U.S. Food and Drug Administration (FDA) for 
treatment of various cancer types (Table 1). 
However, these drugs are costly, have a long list 
of undesirable side effects, and are still not 
effective enough to have a significant effect on 
the course of the disease. Before the modern 
chemotherapy era, drugs derived from natural 
sources were used for centuries for both cancer 
prevention and treatment. According to some 
estimates, as many as 80% of all anticancer 
drugs today have their roots in natural prod-
ucts. The molecular targets of these natural 
compounds and their true potential against 
cancer, however, are not fully understood. 
One of the most important of these natural 
compounds is curcumin (diferuloylmethane), a 
yellow dye that was identified more than a cen-
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Table 1. FDA-approved anticancer drugs and their targets
Year Drug Trade Name Target Cancer type
1952 Leucovorin Wellcovorin Thymidylate synthase Colorectal
1957 Chlorambucil Leukeran DNA CLL, Hodgkin lymphoma, NHL
1963 Vincristine Oncovin, Vincasar PFS β-tubulin ALL, Hodgkin lymphoma, NHL, Rhabdomyo-
sarcoma, Wilm tumor 
1964 Vinblastine Velban Mitotic spindle; Breast, Head and neck, Hodgkin lymphoma, 
Lung
1969 Cytarabine Cytosar, Tarabine PFS DNA ALL, AML, CML, Meningeal leukemia
Procarbazine Matulane DNA Hodgkin lymphoma
1973 Bleomycin Blenoxane DNA; RNA Cervical, Hodgkin lymphoma, Lung, MPE, 
NHL, Testicular, Vulvar
1975 Dacarbazine DTIC-Dome DNA Hodgkin lymphoma, Metastatic melanoma 
1977 Tamoxifen citrate Soltamox ER Breast
1978 Cisplatin Platinol, Platinol-AQ DNA Lung, Mesothelioma, Ovarian 
1979 Daunorubicin Cerubidine DNA AML, ALL
1988 Ifosfamide Ifex DNA Breast, Lung, Lymphoma, Osteosarcoma,  
Ovarian, Testicular
Methotrexate Trexall Folic acid reductase ALL, Breast, GTD, Hodgkin lymphoma,  
Osteosarcoma 
1991 Fludarabine Fludara, Oforta DNA CLL
1993 Paclitaxel Onxol, Taxol Microtubule Ovarian, AIDS-related Kaposi sarcoma*, 
Breast**
1994 Etoposide VePesid,Toposar,Etopophos DNA topoisomerase II Ewing sarcoma, Lung, Testicular
Pegaspargase Oncaspar Asparagine ALL
1996 Anastrozole Arimidex Aromatase Breast
Docetaxel Taxotere, Docefrez β-tubulin Breast, Gastric, Head and neck, Lung, 
Prostate 
Gemcitabine Gemzar DNA Breast, Lung, Ovarian, Pancreatic
1997 Rituximab Rituxan CD20 CLL, NHL 
Toremifene Fareston ER Breast
Letrozole Femara Aromatase Breast
1998 Aldesleukin Proleukin IL-2R Melanoma, Renal
Irinotecan Camptosar DNA topoisomerase I Colorectal
Trastuzumab Herceptin HER-2 Metastatic breast, Gastric*
Infliximab Remicade TNF-α Crohn disease, Colorectal cancer
1999 Denileukin diftitox Ontak IL-2R Cutaneous T-cell lymphoma
Doxorubicin Adriamycin DNA topoisomerase II ALL, AML, Bone, Bladder, Breast, Gastric, 
Hodgkin lymphoma, Neuroblastoma, NHL, 
Ovarian, Thyroid, Wilm tumor
Epirubicin Ellence, Pharmorubicin DNA topoisomerase II Breast
Exemestane Aromasin Aromatase Breast
2000 Arsenic trioxide Trisenox DNA AML
Bexarotene Targretin Retinoid X receptor Cutaneous T-cell lymphoma
Gemtuzumab ozagamicin Mylotarg CD33 AML
Leuprolide acetate Eligard, Lupron GNRH receptor Prostate
Temozolomide Temodar DNA Anaplastic astrocytoma, Glioblastoma 
multiforme
2001 Alemtuzumab Campath CD52 CLL
Capecitabine Xeloda DNA Breast, Colorectal
Imatinib Gleevec Bcr-Abl, CML, Gastrointestinal*
2002 5-Fluorouracil Adrucil,Carac, Efudex DNA Basal cell carcinoma, Breast, Colorectal,  
Gastric, Pancreatic
Fulvestrant Faslodex ER Breast
Ibritumomab tiuxetan Zevalin CD20 NHL
Oxaliplatin Eloxatin DNA Colorectal
2003 Abarelix Plenaxis GNRH receptor Advanced Prostate
Bortezomib Velcade Proteasome, NF-κB Multiple myeloma
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Gefitinib Iressa EGFR NSCLC
Tositumomab and I 131 Bexxar CD20 NHL
2004 Azacitidine Vidaza DNA; RNA Myelodysplastic syndrome
Bevacizumab Avastin VEGF;VEGFR Colorectal, Glioblastoma, Lung, Renal*
Cetuximab Erbitux EGFR Colorectal, Head and neck
Clofarabine Clolar DNA ALL 
Erlotinib Tarceva EGFR Lung, Prostate 
2005 Lenalidomide Revlimid NF-κB Multiple myeloma, Myelodysplastic syndrome
Nelarabine Arranon DNA ALL
Sorafenib tosylate Nexavar B-RAF; VEGFR; PDGFR Liver, Renal 
2006 Dasatinib Sprycel Bcr-Abl; PDGFR; Src ALL, CML
Decitabine Dacogen DNA Myelodysplastic syndrome
Panitumumab Vectibix EGFR Colorectal
Sunitinib malate Sutent PDGFR; VEGFR Gastrointestinal, Renal, Pancreatic neuroen-
docrine tumors* 
Vorinostat Zolinza HDAC Cutaneous T-cell lymphoma
2007 Ixabepilone Ixempra β-tubulins Breast
Lapatinib ditosylate Tykerb HER-2; EGFR Breast
Nilotinib Tasigna Bcr-Abl CML
Raloxifene Evista ER Breast
Temsirolimus Torisel mTOR; HIF-1; VEGF Renal
Topotecan Hycamtin DNA topoisomerase I Cervical, Lung, Ovarian 
2008 Bendamustine Treanda DNA CLL, Hodgkin lymphoma, Lung, Multiple 
myeloma, NHL 
Plerixafor Mozobil CXCR4 MM, NHL 
Adalimumab Humira TNF-α Crohn disease, Colorectal cancer
2009 Degarelix Firmagon GNRH receptor Prostate
Everolimus Afinitor, Zortress mTOR, mTORC1, TSC Renal, Astrocytoma, Advanced pancreatic 
neuroendocrine tumors*, Renal angiomyoli-
poma**
Ofatumumab Arzerra CD20 CLL
Pazopanib Votrient VEGFR; PDGFR Renal, Soft tissue sarcoma*
Pemetrexed Alimta Folate-dependent meta-
bolic processes
Mesothelioma, Lung
Pralatrexate Folotyn Folate carrier type 1 Peripheral T-cell lymphoma
Romidepsin Istodax HDAC Cutaneous T-cell lymphoma
2010 Cabazitaxel Jevtana Microtubule Prostate 
Denosumab Prolia, Xgeva RANKL Multiple myeloma, Bone
Eribulin mesylate Halaven Microtubule Breast
2011 Ipilimumab Yervoy CTLA-4 Melanoma, Metastatic melanoma
Vandetanib Caprelsa EGFR Thyroid cancer
Brentuximab Adcetris CD30 Hodgkin lymphoma, Anaplastic large cell 
lymphoma
Peginterferon Pegintron α-2b interferon receptors Melanoma
Crizotinib Xalkori ALK, ROS1 NSCLC
Vemurafenib Zelboraf B-RAF B-RAF–positive melanoma
2012 Vismodegib Erivedge GLI1 Basal cell carcinoma
Axitinib Inlyta VEGFR; PDGFR Advanced renal cell carcinoma
Pertuzumab Perjeta HER-2 HER-2–positive metastatic breast cancer
Tofacitinib Jakafi, Ruxolitinib JAK2 Myelofibrosis
Cancer types: ALK, anaplastic lymphoma kinase; ALL, acute lymphoblastic leukemia; AML, acute myelogenous leukemia; CLL, chronic lymphocytic leukemia; CML, chronic 
myelogenous leukemia; GTD, gestational trophoblastic disease; MPE, malignant pleural effusion; NHL, non-Hodgkin lymphoma; NSCLC, non-small cell lung carcinoma. Tar-
gets: B-RAF, oncogenic protein encoded by B-Raf gene; Bcr-Abl, fusion protein of ABL part of chromosome 9 breaks and BCR part of chromosome 22; CD20, B-lymphocyte 
antigen; CD30, anaplastic large cell lymphoma–associated marker; CD33, myeloid-associated marker; CD52, mature lymphocytes antigen; COX-2, cyclooxygenase-2; 
CTLA-4, cytotoxic T lymphocyte-associated antigen 4; CXCR4, chemokine receptor 4; EGFR, epidermal growth factor receptor; ER, estrogen receptor; GLI-1, Hedgehog 
Pathway Transcription Factor; GNRH, gonadotropin-releasing hormone; HDAC, histone deacetylases; HER-2, human epidermal growth factor receptor 2 (also known as Neu 
and ErbB-2), HIF-1, hypoxia-inducible factor 1; IκBα, inhibitor of NF-κB transcription factor; IL-2R, interleukin-2 receptor; mTOR, mammalian target of rapamycin; mTORC1, 
mammalian target of rapamycin complex 1; NF-κB, nuclear factor kappa-light-chain-enhancer of activated B cells; PDGFR, platelet-derived growth factor receptor; RANKL, 
receptor activator of NF-κB ligand; ROS1, c-ros oncogene1, receptor tyrosine kinase; Src, oncoprotein; TSC, tuberous sclerosis complex; VEGF, vascular endothelial growth 
factor; VEGFR, vascular endothelial growth factor receptor. FDA approved drugs against another cancer type, Bevacizumab approved in 2009*; Everolimus approved in 
2011* & 2012**; Imatinib approved in 2002*; Paclitaxel approved in 1997* & 2005**; Pazopanib approved in 2012*; Sunitinib malate approved in 2011*; Trastuzumab 
approved in 2010*.
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tury ago. Curcumin is found in turmeric, a yel-
low-colored spice of the perennial herb 
Curcuma longa, which has been used widely for 
centuries not only in cooking but in traditional 
therapies for various diseases, especially as an 
anti-inflammatory agent. Curcumin and its 
metabolite, tetrahydrocurcumin have been 
extensively investigated as anti-inflammatory 
and anti-cancer molecules [3, 4]. 
The wide variety of medicinal effects of curcum-
in is a result of its ability to interact with a 
diverse range of molecular targets (Table 2), 
acting upon numerous biochemical and molec-
ular cascades [5]. This polyphenol modulates 
various targets through either direct interaction 
or modulation of gene expression, which 
includes inflammatory biomarkers, growth fac-
tors and their cell signaling pathways, protein 
kinases and protein phosphatases, tumor sup-
pressor genes, transcription factors, proapop-
totic pathways, and oncoproteins (Table 2). 
Curcumin can also bind directly to DNA and 
RNA. Direct binding to its β-diketone moiety is 
facilitiated, while interaction with other macro-
molecules is mediated through the α, 
β-unsaturated β-diketone moiety, carbonyl and 
enolic groups of the β-diketone moiety, methoxy 
and phenolic hydroxyl groups, and phenyl rings 
[6]. As a result of these interactions, curcumin 
can inhibit tumor proliferation, growth, metas-
tasis, invasion, and angiogenesis. Curcumin 
has been shown to induce cell death mainly 
through apoptosis, but in cells that are apopto-
sis resistant, it has been shown to induce 
mitotic catastrophe [7] and autophagy [8]. 
This review examines curcumin’s interactions 
with a diverse range of major anticancer tar-
gets in multiple cancer types (Table 2) and 
compares its actions with those of FDA-
approved anticancer drugs.
Cancer targets
A desirable anticancer drug must be selective 
for and cytotoxic to cancer cells, have minimal 
side effects, and be cost-effective. Since 1952, 
89 drugs have been approved by the FDA for 
the treatment of various cancer types (Table 1). 
The targets for these drugs have been identi-
fied in phenotypic or correlative studies as 
causal factors in the initiation and/or progres-
sion of a cancer type [9, 10]. Agents that selec-
tively target cancer-specific mutations are 
effective because they can discriminate 
between normal and malignant forms [11]. 
However, most targets are not cancer specific; 
for example, CD20 is a normal B-cell differenti-
ation protein, and epidermal growth factor 
receptor (EGFR) is also expressed on normal 
cells [12].
Targets with FDA-approved drugs
All the anticancer drugs approved by the FDA 
(Table 1) can be subdivided into three groups: 
semiselective, cytotoxic, and tissue-selective. 
The drugs that target growth factor signaling 
and oncoproteins such as EGFR and Bcr-Abl are 
semiselective; those that target cellular compo-
nents such as DNA, DNA topoisomerase, or 
microtubules are cytotoxic; and those that tar-
get cell-surface proteins such as CD20 and 
CD52 are tissue-selective [12]. Semiselective 
agents are typically combined with a cytotoxic 
agent, since semiselective agents are not effec-
tive alone and cytotoxic agents are too toxic 
alone [12]. For example, trastuzumab inhibits 
ErbB2/HER-2, whose overexpression blocks 
paclitaxel-induced apoptosis. Yu et al. were 
able to restore the apoptotic response to pacli-
taxel by administering trastuzumab with it [13]. 
The targets of the semiselective agents (growth 
factors and oncoproteins) and the cytotoxic 
agents (cellular components) are all targets of 
curcumin (Figure 1). Therefore curcumin can be 
classified as both a semiselective and a cyto-
toxic agent.
This section highlights cancer-related targets 
that are modulated by curcumin as well as one 
or more FDA-approved drugs.
Inflammatory biomarkers
Various inflammatory biomarkers are modulat-
ed through suppression of a major inflammato-
ry transcription factor, nuclear factor–kappaB 
(NF-κB), which is constitutively expressed in 
almost all cancer types. Bortezomib and 
lenalidomide, two drugs approved by the FDA 
for the treatment of multiple myeloma and 
myelodysplastic syndrome, inhibit the activa-
tion of NF-κB, thereby disrupting the cell cycle 
and inducing apoptosis in cancer cells. 
Bortezomib kills cancer cells by interfering with 
the action of a large cellular structure called 
the proteasome, which degrades proteins that 
regulate cell proliferation. Resistance against 
bortezomib prompted clinical trials of various 
Cancer targets and curcumin
332 Int J Biochem Mol Biol 2012;3(4):328-351
Table 2. Modulation of cancer-linked cell-signaling pathways by curcumin
Inflammatory biomarkers:
  Inhibited carrageenan-induced rat paw edema and cotton pellet granuloma [139]
  Inhibition of 5-HETE formation in intact human neutrophils [51] 
  Inhibited lipoxygenase and cyclooxygenase in mouse epidermis [52]
  Inhibited activation of NF-κB induced by TNF-α in human leukemia cells [16]
  Inhibited production of TNF-α in a human monocytic macrophage cell line [22]
  Inhibited MMP-9 in human hepatocellular carcinoma cell line [58]
  Inhibited transcription of COX-2 in gastrointestinal cancer cell lines [56]
  Inhibited IL-6 in human osteoblast and osteosarcoma cell lines [55]
  Blocked PYK2 phosphorylation in smooth muscle cells [64]
  Inhibited MMP-2 in H-ras MCF10A cells [59]
  Inhibited DUBs in various colon cancer cells [19]
  Inhibited STAT3 phosphorylation in multiple myeloma [53]
  Inhibited FAK in melanoma cells [62]
  Inhibited p300/CBP-HAT activity in HeLa cells [60]
  Inhibited the catalytic activities of 5-LOX in HT-29 human colon cancer cells [140]
  Inhibited inducible and constitutive iNOS expression in melanoma cells [141]
  Downregulated EZH2 expression in breast cancer cell line [66]
  Reduced HDAC expression in B-non-Hodgkin lymphoma cell line [28] 
Modulation of growth factors and their cell signaling pathway:
  Induced cell cycle inhibitor p21 in human basal cell carcinoma cells [72]
  Inhibited TGF-β expression in transformed keratinocyte [68]
  Inhibited induction of VEGF in osteoblastic cells [35]
  Upregulated p27 in immortalized human umbilical vein endothelial cells [142]
  Inhibited CDK4 activation in various carcinoma cell lines [71]
  Inhibited PDGFR-induced proliferation of human hepatic myofibroblasts [34]
  Inhibited constitutive activation of EGFR in colon cancer cells [29]
  Down-regulated CDK2 in A549 cells [70]
  Abrogated IGF-1R activation in MCF-7 cells [30]
  Decreased expression of VEGFR1 in bladder cancer cells [36]
  Reduced activation of p185/neu/HER-2 in cancer cells [31, 32]
Modulation of protein kinases and protein phosphatases:
  Suppressed PKC activity in NIH 3T3 cells [73]
  Inhibited PKA which inhibited growth of various cancer cells [75]
  Inhibition of cyclic AMP-dependent protein kinase [76]
  Blocked JNK activation in fibroblast cells [83]
  Inhibited PI3-K activation in breast cancer cells [78]
  Inhibited AKT activation in LNCaP and PC-3 but not in DU-145 cells [79]
  Activated Src homology 2 domain-containing tyrosine phosphatase 2 in brain microglia [85]
  Inhibited activation of p38 MAPK in keratinocyte cells [80]
  Dephosphorylated GSK3 in T-cell acute lymphoblastic leukemia cells [84]
  Inhibited mTOR in various cancer cells [39]
  Downregulated B-RAF in fibroblast cells [38]
  Downregulated p-ERK1/2 levels in pancreatic adenocarcinoma cell lines [81]
  Upregulates MAPK phosphatase-5 in prostate cells [87]
  Activated AMPK to inhibit growth in ovarian cancer cells [77]
  Inhibited Akt/mTOR signaling through stimulation of calyculin A-sensitive PTPase [86]
  Activated mitogen-activated protein kinase phosphatase-1 in hippocampal cells [88]
Upregulation of tumor suppressor genes:
  Induced apoptosis in human basal cell carcinoma cells by upregulation of p53 [72]
  Upregulated PTEN expression [91]
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  Inhibited COP9 signalosome-specific phosphorylation linked to p53 degradation by UPS [89]
  Inhibited CDK4-mediated phosphorylation of retinoblastoma protein in cancer cells [71]
Modulation of various transcription factors:
  Downregulated AP-1 activation in mouse fibroblast cells [93]
  Downregulated ER expression in breast cancer cells [42]
  Downregulated transactivation and expression of AR in prostate cancer cells [94]
  Decreased activation of β-catenin in colon cancer cells [95]
  Blocked induction of GADD45 in colon cancer cells [96]
  Increased GADD153 in colon cancer cells [97]
  Inhibited STAT1 phosphorylation in multiple myeloma [53]
  Destabilized HIF-1β (ARNT) in various cancer cells [100]
  Inactivated constitutively active FOXO in T-cell acute lymphoblastic leukemia cells [84]
  Downregulated the expression of PPARδ in HT-29 colon cells [101]
  Downregulated HIF-1α in vascular endothelial cells [99]
  Activated Nrf2 in epithelial cells [102]
Modulation of proapoptotic pathways:
  Decreased Bcl-2 levels in leukemia and colon adenocarcinoma cells [104]
  Downregulated Bcl-xL in B-cell lymphoma [105]
  Upregulated Bax in breast carcinoma cell lines [110]
  Suppressed XIAP to human melanoma cell lines [106]
  Stimulated the activity of caspase-8 in gastric and colon cancer cells [112]
  Activated caspase-8, BID cleavage and cytochrome c release [111]
  Upregulated Bak in acute myelogenous leukemia [96]
  Downregulated c-FLIP in natural killer/T-cell lymphoma cells [107]
  Suppressed expression of IAP-1 in breast cancer cells [108]
  Inhibited IAP-2 in human hepatic cancer cells [109]
  Downregulated survivin in apoptosis-resistant Bcr-Abl–expressing cells [7]
  Induced expression of PUMA, Bim and Noxa in prostate cancer cells [90]
  Activated cysteine proteases for apoptosis in tumor cells [143]
Modulation of oncoproteins:
  Inhibited c-Myc mRNA expression in smooth muscle cells [115]
  Inhibited induction of endogenous c-Met gene in hepatocellular carcinoma cells [118] 
  Decreased expression of Ras and Fos proto-oncogenes in tumorous skin [120]
  Abrogated of Src activity in fibroblast cells [45]
  Downregulated Bcr-Abl fusion gene in human chronic myelogenous cells [46]
  Downregulated Mdm2 in various cancer cells [144]
  Downregulated  N-Myc in medulloblastoma cells [116]
Targets: 5-HETE, 5-hydroxy-eicosatetraenoic acid; 5-LOX, 5-lipoxygenase; AKT, AKT8 virus oncogene cellular homolog; AMPK, 
AMP- activated protein kinase; AP-1, activator protein 1; AR, androgen receptor; ARNT, aryl hydrocarbon receptor nuclear trans-
locator; Bak, B-cell lymphoma 2 homologous antagonist/killer; Bax, B-cell lymphoma 2-associated X protein; Bcl-2, B-cell lym-
phoma 2; Bcl-xL, B-cell lymphoma-extra large; BID, BH3 interacting-domain death agonist; Bim, BH3-only proapoptotic protein; 
B-RAF, oncogenic protein encoded by B-RAF gene; CDK2, cyclin-dependent kinase 2; CDK4, cyclin-dependent kinase 4; c-FLIP, 
cellular FLICE-inhibitory protein; COX-2, cyclooxygenase-2; DUBs, deubiquitinating enzymes; EGFR, epidermal growth factor 
receptor; ER, estrogen receptor; EZH2, enhancer of zeste homolog 2; FAK, focal adhesion kinase; FOXO, forkhead box O; GADD 
45, growth arrest and DNA damage gene 45; GADD153, growth arrest and DNA damage-inducible gene 153; GSK3, glycogen 
synthase kinase 3; HAT, histone acetyltransferases; HDAC, histone deacetylase; HER-2, human epidermal growth factor receptor 
2 (also known as Neu and ErbB-2); HIF-1α, hypoxia-inducible factor-1alpha; IAP-1, inhibitor of apoptosis protein 1; IAP-2, inhibitor 
of apoptosis protein 2; IGF-1R, insulin-like growth factor-1 receptor; IL-6, interleukin-6; iNOS, inducible nitric oxide synthase; JNK, 
cJun N-terminal kinase; MAPK, mitogen-activated protein kinase; MMP-2, matrix metalloproteinase-2; MMP-9, matrix metal-
loproteinase-9; mTOR, mammalian target of rapamycin; NF-κB, nuclear factor kappa-light-chain-enhancer of activated B cells; 
Noxa, phorbol-12-myristate-13-acetate-induced protein 1; Nrf2, NF-E2 related factor 2; PDGFR, platelet-derived growth factor 
receptor; p-ERK 1/2, phosphorylated extracellular signal-regulated protein kinases 1 and 2; PI3-K, phosphotidylinositol-3-kinase; 
PKA, protein kinase A; PKC, protein kinase C; PPARδ, peroxisome proliferator-activated receptorδ; PTEN, phosphatase and tensin 
homolog; PUMA, p53 upregulated modulator of apoptosis; PYK2, proline-rich tyrosine kinase 2; STAT1, signal transducer and 
activator or transcription 1; STAT3, signal transducer and activator of transcription 3;  TGF-β, transforming growth factor-β; TNF-α, 
tumor necrosis factor-alpha; VEGF, vascular endothelial growth factor; VEGFR1, vascular endothelial growth factor receptor 1; 
XIAP, X-linked inhibitor of apoptosis protein.
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second-generation proteasome inhibitors, such 
as marizomib and carfilzomib [14, 15]. 
Not only does curcumin inhibit both inducible 
and constitutive activation of NF-κB in various 
cancer cells [16], it is also a potent proteasome 
inhibitor: it directly inhibits the 20S proteasome 
and induces degradation of IκBα [16, 17]. 
Curcumin also inhibits the COP9 signalosome 
kinases and deubiquitinating enzymes, thereby 
disabling the ubiquitin-proteasome system [18, 
19]. The COP9 signalosome has kinase activity 
that phosphorylates IκBα [18], and curcumin 
has been identified as an efficient inhibitor of 
these kinases [20]. Deubiquitinating enzymes 
are regulators of the ubiquitin-proteasome 
pathway, and ubiquitin-mediated events play 
important roles in cell proliferation. In many 
human cancer types, mutated deubiquitinating 
enzymes have been seen to function as onco-
genes and tumor suppressors [21], implicating 
curcumin as an effective proteasome inhibitor 
targeting the ubiquitin-proteasome pathway in 
multiple ways. 
Chronic inflammation is associated with pro-
cesses that contribute to the onset or progres-
sion of cancer. Increased cancer risk is attrib-
uted to genetic damage caused by chronic 
inflammation via production of oxidizing com-
pounds such as reactive oxygen and nitrogen 
species. Four inflammatory biomarkers, tumor 
necrosis factor alpha (TNF-α), CXC receptor 4 
(CXCR4), receptor activator of NF-kB ligand 
(RANKL), and histone deacetylase (HDAC), are 
targets for FDA-approved drugs (Figure 1). The 
inflammatory cytokines have been shown to 
mediate tumorigenesis, and TNF-α, which con-
trols cell survival and apoptosis, is a vital player 
in inflammation and cancer. The two FDA-
approved drugs that target TNF-α are infliximab 
and adalimumab. These drugs are similar and 
work by reducing inflammation induced by TNF-
α. Curcumin inhibited production of TNF-α [22] 
and suppressed the TNF signaling pathways 
[16]. 
The chemokine receptor CXCR4 is expressed 
on multiple cell types, including cancer cells, 
and when bound by its ligand, CXCL12, is 
involved in tumor progression, angiogenesis, 
metastasis, and survival. CXCR4, which helps 
keep stem cells within the bone marrow, is 
blocked by the drug plerixafor, causing the 
Figure 1. Targets with FDA approved drugs. 
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stem cells to be dislodged and released into 
the blood. Xiaoling et al. showed that curcumin 
could inhibit the invasion and metastasis of 
human ovarian cancer cells by inhibiting expres-
sion of CXCL-12 and CXCR4 [23].
The cytokine RANKL triggers migration of 
human epithelial cancer cells and melanoma 
cells that express the receptor RANK. 
Denosumab, a monoclonal antibody, binds 
RANKL, blocking it from triggering the migra-
tion of these cancer cells. Denosumab also tar-
gets osteoclasts to prevent osteoporosis. 
Curcumin inhibited RANKL activation in osteo-
clast precursors and suppresses osteoclasto-
genesis [24].
Histone deacetylases remove acetyl groups 
from many different proteins that regulate gene 
expression, inducing tumor cell differentiation, 
cell cycle arrest, and apoptosis. Two drugs, vori-
nostat and romidepsin, inhibits the activity of 
HDACs. They were approved by the FDA for 
treatment of cutaneous T-cell lymphoma on the 
basis of positive phase II trial data [25-27]. 
Curcumin is a significant HDAC inhibitor, block-
ing expression of various class I HDACs (HDAC1, 
HDAC3, and HDAC8) in Raji cells [28].
Growth factors and their cell signaling path-
ways
Growth factors such as epidermal growth fac-
tor (EGF), platelet-derived growth factor (PDGF), 
and vascular endothelial growth factor (VEGF) 
are major regulatory molecules that control the 
growth of cells. Multiple signaling pathways 
that mediate the normal functions and activi-
Figure 2. Cancer causing genes targeted by curcumin which are unapproved FDA targets.
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ties of these growth factors, such as cell divi-
sion, cell movement, cell responses to certain 
external stimuli, and cell death, are usually 
upregulated in cancer. Recent studies provide 
evidence that curcumin targets these growth 
factors and the signaling pathways they regu-
late; these findings increase our understanding 
of the mechanisms of curcumin’s antiprolifera-
tive and antigrowth activities.
EGFR is a protein found on the surface of some 
cells, and its binding to EGF enables cells to 
divide. It is found at abnormally high levels on 
some types of tumor cells. The FDA has 
approved six anti-EGFR drugs: gefitinib, cetux-
imab, erlotinib, panitumumab, lapatinib ditosyl-
ate, and vandetanib. Gefitinib, erlotinib, and 
lapatinib ditosylate inhibit the tyrosine kinase 
activity of EGFR. Cetuximab binds to the exter-
nal portion of EGFR, preventing its activation by 
growth signals and inhibiting signal transduc-
tion and thus proliferation. Panitumumab and 
vandetanib attach to EGFR and prevent it from 
sending growth signals. Curcumin inhibited the 
constitutive activation of both EGFR and insulin 
growth factor–1 receptor signaling pathways in 
colon cancer cells [29] and MCF-7 breast can-
cer cells [30].
HER-2/erbB2/neu/p185, another member of 
the EGFR superfamily, is overexpressed in 
breast, gastric, lung, colorectal, and head and 
neck cancers. The FDA-approved anti-HER-2 
drugs are trastuzumab for HER2-neu–positive 
breast cancer, lapatinib ditosylate, and pertu-
zumab for HER-2–positive metastatic breast 
cancer; pertuzumab is expensive and prone to 
production problems. Trastuzumab is a mono-
clonal antibody that binds to HER-2, while lapa-
tinib ditosylate inhibits the tyrosine kinase 
activity of HER-2; pertuzumab is another mono-
clonal antibody that binds to HER-2 but at a dif-
ferent region than trastuzumab, preventing 
HER-2 from sending growth-promoting signals. 
Curcumin targets HER-2 effectively [31, 32], 
and its combination with any of these drugs 
could reduce drug dose and cost and circum-
vent supply problems. 
PDGF, through its cell-surface tyrosine kinase 
receptor (PDGFR), stimulates various cellular 
functions, including growth, proliferation, and 
differentiation. PDGF expression as a result of 
autocrine stimulation of cancer cell growth or 
paracrine interactions involving adjacent cells 
has been seen in many types of solid tumors 
[33]. The FDA has approved five anti-PDGFR 
drugs: sorafenib tosylate, dasatinib, sunitinib 
malate, pazopanib, and axitinib, which inhibit 
the tyrosine kinase activity of PDGFR to block 
cell growth and proliferation. Curcumin inhibit-
ed PDGFR-induced proliferation of human 
hepatic myofibroblasts [34]. 
Angiogenic endothelial cells express on their 
surfaces protein receptors for VEGF, angiopoi-
etins, and various other adhesion molecules. 
Overexpression of VEGF and its receptor VEGFR 
has been used widely as a biomarker for angio-
genic activity in cancer. The six FDA-approved 
anti-VEGF and anti-VEGFR drugs are bevaci-
zumab, sorafenib tosylate, sunitinib malate, 
temsirolimus, pazopanib, and axitinib. Beva- 
cizumab binds to VEGF and prevents it from 
interacting with receptors on endothelial cells, 
blocking the step necessary for initiation of 
new blood vessel growth, while the other five 
drugs inhibit the tyrosine kinase activity of 
VEGFR to halt development of new blood ves-
sels. Since curcumin has the ability to inhibit 
both VEGF and VEGFR in various cancer types, 
it might be an effective antiangiogenic agent 
[35, 36].
The growth activation functions of cancer cells 
are continuously switched on, prompting unreg-
ulated growth and proliferation of these cells. 
Kinase inhibitors attack that problem by pre-
venting cancer cells from binding to phosphates 
in the bloodstream and thus halting phosphory-
lation, which is required for cell growth. The cur-
rent trend of development of kinase inhibitor 
drugs that modulate multiple growth factors, 
such as sorafenib tosylate, dasatinib, sunitinib 
malate, lapitinib ditosylate, pazopanib, and 
axitinib, has been strongly supported by the 
FDA. Curcumin also targets all of these potent 
growth factors and might be an effective anti-
growth agent.
Protein kinases and protein phosphatases
Deregulation of cell signaling is a vital part of 
cancer development. The protein kinases and 
protein phosphatases are involved in regulating 
cell signaling pathways that are responsible for 
cell growth, proliferation, and death, such as 
RAS-RAF-MAPK/ERK, JNK, cAMP/PKA, PKC, 
and RTK/PI3K/AKT/mTOR.
B-RAF is a member of the RAF family of serine/
threonine kinases that mediate cellular 
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responses to growth signals through the RAS-
RAF-MAP kinase pathway. Mutated B-RAF pro-
teins have elevated kinase activity and are 
transforming in NIH3T3 cells; inhibition of 
B-RAF’s oncogenic activity decreases tumor 
cell proliferation and increases tumor cell death 
[37]. Two anti-B-RAF drugs have been approved 
by the FDA, sorafenib tosylate for liver and renal 
cancers and vemurafenib for melanoma. 
Sorafenib tosylate inhibits the threonine kinase 
activity of B-RAF, while vemurafenib blocks the 
activity of a permanently activated mutant form 
of B-RAF, B-RAF V600E. Curcumin induced 
heme oxygenase-1 (HO-1), an enzyme with anti-
oxidant, antiangiogenic, and antiapoptotic 
properties mediated by inhibiting B-RAF [38].
mTOR (mammalian target of rapamycin) is a 
serine/threonine kinase in the receptor tyro-
sine kinase/phosphoinositide 3 kinase/AKT/
mTOR (RTK/PI3K/AKT/mTOR) pathway, through 
which it plays a prominent role in regulating the 
growth, proliferation, motility, survival, and 
angiogenesis of cells. This signaling pathway is 
highly active in many cancer cells. The two FDA-
approved anti-mTOR drugs are temsirolimus 
and everolimus. Temsirolimus specifically inhib-
its the serine/threonine kinase mTOR that is 
activated in tumor cells, halting their growth 
and proliferation, while everolimus binds to a 
protein called immunophilin FK binding pro-
tein-12 to form a complex that binds to and 
inhibits the mTOR kinase. mTOR is specifically 
targeted by curcumin in various cancer cells, 
suggesting that curcumin would be an efficient 
anti-mTOR agent [39].
Transcription factors
The transcription factors estrogen receptor 
(ER) and janus kinase 2 (JAK2) are preferen-
tially active in breast cancer cells compared 
with other tumor cell types, and inhibition of 
these transcription factors decreased their 
number and blocked growth of xenografts [40, 
41]. 
Estrogen can stimulate proliferation of cells 
with an inherited or induced mutation, because 
when it binds to the ER on these cells it is able 
to regulate the activity of many different genes 
that promote proliferation and uncontrolled 
growth. The four FDA-approved anti-ER drugs 
are tamoxifen citrate, toremifene, fulvestrant, 
and raloxifene, which are also known as selec-
tive estrogen receptor modulators. Tamoxifen, 
toremifene, and raloxifene bind to ER to pre-
vent estrogen binding, while fulvestrant binds 
to ER to promote its destruction, thereby reduc-
ing estrogen levels inside cells. Aromatase 
inhibitors are another class of FDA-approved 
drugs that interfere with estrogen’s ability to 
promote the growth of ER-positive breast can-
cers. The enzyme aromatase is vital for produc-
tion of estrogen in the body; by blocking its 
activity, estrogen levels in cells are lowered and 
the growth of cancer cells that require estrogen 
is inhibited. Aromatase inhibitors are used 
mostly in menopausal women; they are ineffec-
tive in premenopausal women, whose ovaries 
can produce enough aromatase to overcome 
the inhibition. The three aromatase inhibitors 
approved by the FDA for the treatment of 
ER-positive breast cancer are anastrozole, 
letrozole, and exemestane. Curcumin blocks 
the proliferative action of breast cancer cells by 
downregulating ER activity and can reduce the 
toxic effects of the current drugs [42].
Marotta et al. found that the interleukin 6 (IL-
6)/JAK2/Stat3 pathway was preferentially 
active in CD44+CD24– breast cancer cells com-
pared with other tumor cell types, and inhibi-
tion of JAK2 was able to induce cancer cell 
death and prevent growth of xenografts. The 
authors highlighted the differences between 
distinct breast cancer cell types and identified 
JAK2 as a more specific and effective breast 
cancer therapy than existing regimens [41]. 
JAK2 inhibitor tofacitinib was recently approved 
by the FDA. Curcumin inhibited JAK2 mRNA 
expression in K562 chronic leukemia cells [43].
Oncoproteins
Identification of cancer-specific oncoproteins, 
such as Src, has been an effective approach to 
development of new diagnostics and therapeu-
tics [44]. The Src proto-oncoprotein is activated 
in more than half of human breast and colon 
cancers but, unlike many other oncoproteins, 
its gene is not mutated. This suggests that 
aberrant regulation of Src is involved. Src is pre-
dominantly inactive in cells under normal cir-
cumstances and is switched on only at specific 
times. The FDA-approved drug dasatinib, an 
inhibitor of tyrosine kinase, targets Src family 
kinases in the treatment of acute lymphocytic 
leukemia and acute myelocytic leukemia. 
Curcumin can retard cellular growth and migra-
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tion via downregulation of Src kinase activity 
[45].
The BCR-ABL oncogene was the first chromo-
somal translocation shown to be associated 
with chronic myelogenous leukemia. Three 
FDA-approved drugs target Bcr-Abl: imatinib, 
dasatinib, and nilotinib, all tyrosine kinase 
inhibitors. Imatinib, a potent inhibitor, blocks 
expression of primary tumor angiogenesis reg-
ulators to prevent tumor growth. Curcumin 
inhibited the proliferation of leukemia cells 
through downregulation of the abundant Bcr-
Abl oncoprotein and the RAS signal transduc-
tion pathway in human leukemia cell lines [46].
Cellular components
The FDA-approved cytotoxic anticancer agents 
recognize and destroy cellular components 
such as DNA, RNA, DNA polymerase, mitotic 
spindle/microtubules/β-tubulin, and DNA topoi-
somerase I and II (Table 1).
DNA and RNA are required for growth and mul-
tiplication of cells. Anti-DNA/anti-RNA drugs 
such as cytarabine stop cancer cells from mul-
tiplying by inhibiting the production of DNA and 
RNA, which leads to unbalanced cell growth 
and death. DNA polymerases are enzymes spe-
cialized for replication, repair, or tolerance of 
damaged DNA. Many point mutations that 
occur in cancer cells arise from the error-gener-
ating activities of DNA polymerases, and these 
enzymes have become viable anticancer tar-
gets [47]. Curcumin binds directly to DNA and 
RNA and functions as an anti-DNA/anti-RNA 
drug [6]. It also is a specific inhibitor of DNA 
polymerase [48].
Microtubules (α-tubulin and β-tubulin) are 
important in cell growth and division, develop-
ment, and maintenance of cell shape, motility, 
and signaling. Loss of their equilibrium dynam-
ics often results in development of cancer. The 
FDA has approved three drugs that target 
microtubules, three that target β-tubulin spe-
cifically, and one that targets the mitotic spin-
dle. All seven of these drugs have the same 
effect, inhibition of cell proliferation. The three 
most widely used of these drugs are vincristine 
(anti-β-tubulin), vinblastine (anti–mitotic spin-
dle), and paclitaxel (anti-microtubule). They 
bind to microtubules and prevent the separa-
tion of DNA during cell division, inhibiting cell 
reproduction. They also prevent manufacture of 
DNA, RNA, and proteins. Curcumin has been 
identified as an antimicrotubule agent and 
inhibited cancer cell proliferation by perturbing 
microtubule assembly dynamics in HeLa and 
MCF-7 cells [49].
DNA topoisomerases are essential to maintain-
ing the helical structure of DNA. Five FDA-
approved anticancer drugs, including irinote-
can and etoposide, selectively target DNA 
topoisomerases I and II. Blocking one of these 
enzymes leads to breaks in the DNA and thus 
to cell death. Curcumin induced both topoisom-
erases I and II to trigger death in K562 cells 
[50].
FDA-unapproved targets
The previous section discussed molecular tar-
gets modulated by curcumin for which FDA-
approved targeted drugs are available. There 
are, however, many curcumin targets for which 
no FDA-approved drug is available (Figure 2).
Inflammatory biomarkers 
Although the anti-inflammatory effect of cur-
cumin has been established, its mechanism of 
action is not clear. Some of the early studies of 
inflammatory biomarkers targeted by curcumin 
examined 5-hydroxy-eicosatetraenoic acid 
(5-HETE), cyclooxygenase (COX), and lipoxygen-
ase (LOX), and curcumin’s anti-inflammatory 
activities were shown to be a result of its inhibi-
tion of arachidonic acid metabolism [51, 52]. 
Efforts toward understanding curcumin’s anti-
inflammatory and anticancer activities provid-
ed evidence for its interaction with as many as 
16 potent inflammatory biomarkers, such as 
NF-κB, signal transducer and activator of tran-
scription 3 (STAT3), histone acetyltransferase 
(HAT), HDAC, COX2, 5-LOX, inducible nitric oxide 
synthase (iNOS), TNF-α, IL-6, matrix metallopro-
teinases (MMP)-2 and -9, focal adhesion kinase 
(FAK), proline-rich tyrosine kinase 2 (PYK2), 
deubiquitinating enzymes, 5-HETE, and enha- 
ncer of zeste homolog 2 (EZH2) (Figure 2 and 
Table 2).Curcumin modulates these inflamma-
tory biomarkers through suppression of inflam-
matory transcription factors such as NF-κB [16] 
and STAT3 [53]. These transcription factors are 
constitutively expressed in almost all cancer 
types, and curcumin has been shown to inhibit 
both inducible and constitutive activation of 
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both. As a result, curcumin is able to modulate 
the downstream genes induced by these tran-
scription factors, inhibiting cell proliferation, 
invasion, metastasis, and angiogenesis and 
inducing cell death.
Interleukins are inflammatory cytokines that 
play crucial roles in induction of adhesion mol-
ecules, metalloproteinases, and proangiogenic 
factors that can promote tumor invasion and 
angiogenesis [54]. Curcumin has successfully 
inhibited IL-6, which can stimulate develop-
ment of osteoclasts from their hematopoietic 
precursors [55]. 
Cyclooxygenases catalyze the synthesis of 
prostaglandins from arachidonic acid. COX was 
identified as one of the targets of curcumin 
anti-inflammatory activity [51, 52]. There are 
two isoforms of COX, designated COX1 and 
COX2. COX1 appears in most normal tissues, 
while COX2 is induced by oncogenes, growth 
factors, carcinogens, and tumor promoters. 
Curcumin had no inhibitory effects on COX1 but 
directly inhibited the activity of COX2 [56]. 
Matrix metalloproteinases are involved in tumor 
metastasis [57]. Curcumin suppressed the 
expression of MMP-9 in the highly invasive 
human hepatocellular carcinoma SK-Hep-1 cell 
line to inhibit cellular migration and invasion 
[58]. Similarly, curcumin inhibited an H-ras–
induced invasive phenotype in MCF10A human 
breast epithelial cells by downregulating MMP-2 
[59]. 
Histone acetyltransferases have critical roles in 
various cellular processes, including cell cycle 
control, differentiation, and apoptosis. Curcu- 
min inhibited p300/CBP HAT activity in HeLa 
cells. p300/CBP HAT is known to acetylate sev-
eral nonhistone proteins such as p53, and this 
was confirmed when curcumin inhibited the 
p300-mediated acetylation of p53 in vivo, sup-
pressing its DNA repair activity [60]. 
Focal adhesion kinase is an important modula-
tor of cell proliferation, survival, and migration 
and was demonstrated to be involved in liver 
tumor progression and to have prognostic sig-
nificance in hepatocellular carcinoma [61]. 
Curcumin inhibited FAK activity in melanoma 
cells [62]. Proline-rich tyrosine kinase 2, also 
known as cell adhesion kinase-β, is a tyrosine 
kinase that is structurally related to FAK [63]. 
Pyk2 has been demonstrated to promote 
migration and invasion and mediate angiogen-
esis. Curcumin blocked PYK2 phosphorylation 
in smooth muscle cells [64]. 
The enhancer of zeste homolog 2 is a transcrip-
tional repressor that has been linked to aggres-
sive cancer types such as prostate and breast 
[65]. Curcumin decreased proliferation of MDA-
MB-435 breast cancer cells by downregulating 
the expression of EZH2 [66]. 
Growth factors and their cell signaling path-
ways
Recent findings suggest that curcumin targets 
not only EGF, PDGF, and VEGF but also the 
transforming growth factor (TGF). TGF-β signal-
ing is an important regulator of tumorigenesis, 
and its signaling pathways are often modified 
during tumor progression. TGF-β is able to 
recruit certain cell types that can facilitate 
angiogenesis [67]. Curcumin inhibited TGF-β in 
transformed keratinocytes, the major cell type 
of the epidermis and a primary target of car-
cinogens [68]. 
Several proteins that control the cell cycle are 
tightly regulated to ensure that cells divide only 
when necessary; loss of this regulation is one 
of the hallmarks of cancer. Major control 
switches of the cell cycle are cyclin-dependent 
kinases (CDKs) and their inhibitors. The CDK 
inhibitor p21/WAF1 blocks the activity of CDK2, 
which is required for progression through G1. 
Another inhibitor, p27/KIP1, regulates the G0 to 
early G1 phase transition through CDK2 and 
the G1 to S phase transition through CDK4 and 
CDK6 [69]. Since curcumin targets CDK2 [70], 
CDK4 [71], and p21 [72], it might be very effi-
cient in controlling aberrant cell cycling in 
cancer. 
Protein kinases and protein phosphatases
Protein kinase C (PKC) is a family of serine/
threonine kinases that regulate a diverse set of 
cellular processes, including proliferation, 
apoptosis, survival, and migration. The pattern 
of expression of PKC is profoundly altered in 
various types of cancers, reflecting their 
involvement in disease progression. Curcumin 
was shown to inhibit 12-O-tetradecanoyl-
phorbol-13-acetate–induced tumor promotion 
through inhibition of PKC activity [73]. Protein 
kinases A are ubiquitous intracellular cAMP 
effectors that regulate multiple processes. The 
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cAMP/PKA signaling pathway is altered in vari-
ous cancers [74]. Curcumin is a selective and 
noncompetitive inhibitor of PKA [75]. The 
enzyme 5-AMP-activated protein kinase (AMPK) 
is activated during metabolic stress, and recent 
findings suggest that AMPK activation strongly 
suppresses cell proliferation and induces cell 
apoptosis in a variety of cancer cells. Strong 
p38-dependent activation of AMPK induced 
cytotoxicity in various cancer cells [76, 77]. 
In recent years, it has been shown that the 
PI3K/PKB signaling pathway components are 
frequently altered in human cancers. Curcumin 
has several different molecular targets within 
the PI3K/PKB signaling pathway that could 
contribute to inhibition of proliferation and 
induction of apoptosis. For example, inhibition 
of basal activity of Akt/PKB induced apoptosis 
in breast cells [78] and prostate cancer cells 
[79]. 
p38 mitogen-activated protein kinase (p38 
MAPK) is known as a stress-activated MAPK 
able to promote expression of numerous inflam-
matory agents, such as TNFα, IL-1β, IL-8, COX-2, 
iNOS, prostaglandin E2, MMPs, and vascular 
cell adhesion molecule. Curcumin suppressed 
elevated COX-2 expression by inhibiting p38 
MAPK in ultraviolet B–irradiated keratinocytes 
[80]. Extracellular signal regulated kinase (ERK) 
has two closely related isoforms, ERK1 (44 
kDa) and ERK2 (42 kDa), whose expression is 
elevated in human cancer and implicated in 
rapid malignant cell growth and resistance to 
apoptosis. Curcumin downregulated elevated 
ERK1/2 protein levels in pancreatic adenocar-
cinoma cell lines [81]. That the cJun NH2-
terminal kinase (JNK) pathway is implicated in 
tumor development was shown by studies in 
murine embryo fibroblasts demonstrating that 
loss of JNK caused major defects in cell prolif-
eration [82]. Curcumin blocked N-methyl-N-
nitro-N-nitrosoguanidine–mediated JNK activa-
tion in fibroblasts [83].
The serine/threonine protein kinase glycogen 
synthase kinase 3 (GSK-3) is part of many sig-
naling pathways, including those involved in gly-
cogen production, apoptosis, and stem-cell 
maintenance. Curcumin dephosphorylated and 
thus inactivated constitutively active GSK-3 in 
T-cell acute lymphoblastic leukemia cells [84]. 
Tyrosine phosphorylation, an important signal-
ing mechanism, is controlled by protein-tyro-
sine phosphatases (PTPases). Oncogenic acti-
vation modulated by PTPase is a common 
feature in cancer. With increasing understand-
ing of the oncogenic activity of PTPase, PTP 
inhibitors are considered potential antitumor 
drugs; curcumin should be further investigated, 
as it is an effective PTP inhibitor. For example, 
curcumin activated Src homology 2 domain–
containing tyrosine phosphatase 2, a negative 
regulator of the JAK-STAT pathway, in brain 
microglia [85]; it inhibited Akt/mTOR signaling 
through stimulation of calyculin A–sensitive 
PTPase [86]; it upregulated MAPK phospha-
tase-5 in prostate cells [87]; and it attenuated 
ethanol-induced neurotoxicity by activating 
MAPK phosphatase-1, which acts as the nega-
tive regulator of p38 MAPK in hippocampal 
cells [88]. There are currently no FDA-approved 
drugs that target tyrosine phosphatases.
Tumor suppressor genes
Tumor suppressor genes, such as retinoblasto-
ma (Rb) and p53, are defined by their inactiva-
tion in human cancer. As a result, their main 
function in growth regulation and differentia-
tion is altered. A drug that can upregulate these 
genes is a desirable anticancer agent. Curcumin 
is able to upregulate three important tumor 
suppressor genes, p53, Rb, and PTEN (phos-
phatase and tensin homolog), making it an 
effective antiproliferation and proapoptosis 
agent.
p53, an important cell cycle and apoptosis reg-
ulator, has a major role in eliminating cancer-
prone cells from replicating. Curcumin induced 
apoptosis in human basal carcinoma cells by 
upregulation of p53 [72]. Curcumin inhibited 
the COP9 signalosome-specific phosphoryla-
tion linked to p53 degradation by the ubiquitin-
proteasome system [89].
PTEN protects cells from growing and dividing 
too rapidly or in an uncontrolled way by trigger-
ing apoptosis. It also inhibits migration, inva-
sion, and angiogenesis. Somatic mutations in 
the PTEN gene are among the most frequent 
genetic changes in human cancers. In one 
study, wild-type PTEN enhanced curcumin-
induced apoptosis and, in contrast, inactive 
PTEN inhibited curcumin-induced apoptosis 
[90]. Upregulation of PTEN expression was to 
inhibit vascular smooth muscle cell prolifera-
tion and arterial restenosis [91].
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The Rb protein plays a pivotal role in negative 
control of cell cycle and tumor progression. 
Loss of its functions may induce cell cycle 
deregulation, which would lead to a malignant 
phenotype. Curcumin inhibited hyperphosphor-
ylation of Rb and cell cycle deregulation in pros-
tate cancer cells [92] and inhibited CDK4-
mediated phosphorylation of Rb protein in 
cancer cells [71].
Transcription factors 
The transcription factor activator protein (AP-1), 
androgen receptor (AR), β-catenin, growth 
arrest DNA damage (GADD), STATs, hypoxia 
inducible factor (HIF-1), Forkhead family of tran-
scription factors (FOXO), peroxisome prolifera-
tor-activated receptor (PPARδ), and NF-E2-
related factor 2 (Nrf2) are important transc- 
ription factors that are upregulated in most 
cancers. They are involved in cell growth and 
proliferation, apoptosis, invasion, metastasis, 
angiogenesis, and resistance to cancer 
therapy. 
c-Fos forms a functional heterodimer complex 
with c-Jun to enable formation of the AP-1 com-
plex, which is responsible for tumor cell prolif-
eration and transformation. Curcumin inhibited 
tumor progression by decreasing expression of 
c-Fos, inhibiting AP-1 complex formation in 
fibroblasts [93]. 
Androgen binding and acting through its recep-
tor is vital in the normal development and main-
tenance of the prostate. Mutations of AR and 
its coregulators play important roles in prostate 
cancer progression by contributing to differ-
ences in AR ligand specificity or transcriptional 
activity. Curcumin is an effective anti-AR agent 
that downregulated the transactivation of both 
AR and AR-related cofactors AP-1, NF-κB, and 
CREB-binding protein in two prostate cancer 
cell lines [94]. 
β-catenin is an important protein in cancer pro-
motion and progression of various malignan-
cies, such as colon cancer, melanoma, hepato-
cellular carcinoma, ovarian cancer, endometrial 
cancer, medulloblastoma pilomatricomas, and 
prostate cancer. Curcumin inhibited cancer pro-
motion by decreasing activation of β-catenin in 
colon cancer cells [95]. 
GADD controls two functions: it is a positive 
regulator of growth inhibition and apoptosis 
and a negative regulator of cell cycle arrest and 
apoptosis. Curcumin blocked induction of 
GADD45 [96] and increased expression of pro-
apoptotic GADD153 in colon cancer cells [97].
The STATs, upon binding to a JAK, translocate to 
the nucleus to induce or modulate expression 
of target genes. Numerous reports have shown 
that STATs are constitutively activated in a vari-
ety of tumors. Curcumin downregulated expres-
sion of Bcl-xL and cyclinD1 by inhibiting activa-
tion of both STAT3 and STAT1 in multiple 
myeloma [53].
Hypoxia-inducible factor 1 activates the tran-
scription of genes involved in angiogenesis, cell 
survival, glucose metabolism, and invasion. To 
date, there is only one drug that targets HIF-1, 
temsirolimus, which was approved by the FDA 
for treatment of renal cancer and is highly 
effective [98]. Curcumin reduced expression of 
HIF-1 cofactors HIF-1α [99] and ARNT [100] in 
various cancer cells, suggesting that it would 
be an effective anti-HIF agent in cancer 
therapy.
Forkhead box O transcription factors are 
involved in multiple signaling pathways and 
play critical roles in promotion and progression 
of cancer. These factors are important sub-
strates of the protein kinase AKT. Curcumin 
downregulated constitutively active FOXO, lead-
ing to inhibition of proliferation and induction of 
caspase-dependent apoptosis in T-cell acute 
lymphoblastic leukemia cells [84].
Peroxisome proliferator-activated receptors are 
ligand-activated transcription factors that have 
been implicated in the disease-related pro-
cesses of inflammation and cancer. Curcumin 
downregulated VEGF through inhibition of 
PPARδ in colon cancer cells [101]. 
Nrf2 is an important regulator of cellular 
responses to oxidative stress and is regulated 
by Keap1 for proteasomal degradation. The 
Nrf2/Keap1 system is dysregulated in lung, 
head and neck, and breast cancers, and this 
affects cellular proliferation and response to 
therapy. Curcumin significantly increased 
expression of HO-1 (a redox-sensitive inducible 
protein that provides protection against various 
forms of stress) through stimulation of Nrf2 
[102]. 
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Proapoptotic pathways
Studies in p53-null mice show increases in the 
occurrence of premature tumors, strong evi-
dence that apoptotic genes are critical to tumor 
development. It is therefore not surprising that 
most anticancer treatments act through apop-
tosis [103]. Curcumin induced cell death by 
modulating a majority of the apoptotic genes; it 
downregulated antiapoptotic Bcl-2 [104], Bcl-xL 
[105], survivin [7], XIAP [106], c-FLIP [107], 
IAP-1 [108], and IAP-2 [109], while upregulating 
proapoptotic genes Bax [110], Bak [96], BID 
[111], PUMA, Bim, and Noxa [90] in various 
cancer types. Its numerous apoptotic targets 
hint at curcumin’s anticancer potential. 
Caspase-8 is a cysteine protease required for 
induction of apoptosis through proper signaling 
via the death receptor (extrinsic) pathway. 
Dysregulation of caspase-8 expression or func-
tion contributes to cancer formation and pro-
gression. Inactivation of caspase-8 promotes 
resistance to current treatment approaches 
that induce apoptosis via the death receptor 
pathway. Therefore, the restoration of cas-
pase-8 function is important in overcoming this 
resistance. Curcumin stimulated caspase-8 
activity in gastric and colon cancer cells and 
induced cell death [112]. Curcumin also 
induced non-apoptotic cell death, such as 
autophagic cell death, through degradation of 
Beclin-1 and accumulation of microtubule-
associated protein 1 light chain 3 [113].
Oncoproteins
Oncoproteins are one of the most important 
contributors to tumorigenesis, and curcumin 
targets most of the important oncoproteins, 
such as Mdm2, c-Myc, N-myc, c-Met, Ras, and 
Fos, that are linked to major cancer types. The 
three closely related Myc family proteins (c-Myc, 
N-Myc, and L-Myc) regulate a varied range of 
gene products, including cell-cycle factors, 
transcription factors, growth factor receptors, 
and angiogenesis inhibitors [114]. Curcumin 
downregulated c-Myc [115] and N-Myc [116] in 
various cancer types. 
c-Met is a family of oncogenes that regulate 
important cellular processes, such as differen-
tiation, proliferation, cell cycle, motility, and 
apoptosis. These changes in c-Met have been 
seen in solid tumors, such as lung cancer, 
mesothelioma, colon cancer, head and neck 
cancer, esophageal cancer, gastric cancer, 
pancreatic cancer, sarcomas, thyroid cancer, 
ovarian cancer, breast cancer, cervical cancer, 
brain tumors, and especially hereditary papil-
lary renal cell carcinomas [117]. Curcumin 
blocked transactivation of the c-Met promoter 
by AP-1 and inhibited induction of endogenous 
c-Met in hepatocellular carcinoma cells to 
inhibit cell growth and differentiation [118].
In a study on the development of colorectal 
cancer, the expression of Ras, Jun, and Fos 
oncoproteins occurred significantly more often 
in large tubulovillous adenomas and adenocar-
cinomas than in normal human colons [119]. 
Curcumin decreased the expression of two 
potent proto-oncogenes, Ras and Fos, in tumor-
ous skin [120].
In many cellular stress pathways, such as DNA 
damage, hypoxia, telomere shortening, and 
oncogene activation, there is rapid stabilization 
of p53 via blockade of its degradation by its 
specific E3 ubiquitin ligase, Mdm2 [121]. 
Curcumin downregulated Mdm2, which result-
ed in p53 stabilization in various cancer cells 
[122].
Synergistic effects of curcumin with FDA-
approved drugs
The current focus in targeted therapies is on 
combinations with traditional therapies; such 
combinations are thought to decrease side 
effects and toxicity without compromising ther-
apeutic efficacy. Navis et al. found that curcum-
in enhanced the antitumor effects of cisplatin 
when used in combination against fibrosarco-
ma [123]. NF-κB has been implicated in the 
development of cancer cell resistance to drugs 
such as doxorubicin, 5-FU, cisplatin, and pacli-
taxel. In a study that pretreated cancer cells 
with common biologic modulators such as 
tamoxifen, dexamethasone, or curcumin, doxo-
rubicin-induced NF-κB activation was attenuat-
ed significantly. This inhibition may overcome 
the problem of drug resistance and contribute 
to sensitization of cancer cells to chemothera-
peutic drugs [124]. Synergistic inhibition of pro-
liferation resulted when curcumin was com-
bined with FDA-approved drugs such as 
cisplatin and 5-FU to treat a variety of human 
cancer cells [125, 126]. Chirnomas et al. found 
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that curcumin sensitized ovarian and breast 
tumor cells to cisplatin through apoptotic cell 
death, while Du et al. demonstrated synergism 
between curcumin and 5-FU at higher doses 
against the human colon cancer cell line HT-29; 
the synergism was associated with decreased 
expression of COX2 protein. Waly et al. provid-
ed evidence that curcumin significantly amelio-
rated oxidative stress induced by either cispla-
tin or oxaliplatin in HEK cells by significantly 
inhibiting the activities of the antioxidant 
enzymes and reducing the concentrations of 
glutathione and total antioxidant capacity 
[127].
Curcumin has been administered in combina-
tion with celecoxib, a specific COX2 inhibitor, to 
treat colorectal cancer [128]. The rationale for 
combining curcumin and celecoxib was that 
both drugs inhibit COX2 by different mecha-
nisms: curcumin downregulates COX2 mRNA 
and protein levels [56, 129], whereas celecoxib 
inhibits COX2 directly by binding to its active 
site [130].
In a preclinical study that evaluated the antitu-
mor activity of liposomal curcumin with oxalipl-
atin in colorectal cancer, there was synergism 
between these two compounds at a ratio of 4:1 
in LoVo cells, and significant tumor growth inhi-
bition was observed in Colo205 and LoVo xeno-
grafts [131]. In stand-alone analysis, the growth 
inhibition by liposomal curcumin was greater 
than that by oxaliplatin in Colo205 cells. Tumors 
from animals treated with liposomal curcumin 
showed an antiangiogenic effect. Therefore this 
study established that the combination of lipo-
somal curcumin with oxaliplatin had compara-
ble or greater growth-inhibitory and apoptotic 
effects than either agent alone in colorectal 
cancer, both in vitro and in vivo.
At the 2012 Meeting of the American 
Association for Cancer Research, results of a 
phase II study of curcumin and docetaxel in 
castration-resistant prostate cancer were pre-
sented; the combination was synergistic and 
yielded better results than docetaxel alone. 
Curcumin synergistically enhanced the in vitro 
and in vivo antitumor efficacy of docetaxel 
against lung cancer. Simultaneous administra-
tion of curcumin and docetaxel caused little 
toxicity in normal tissues, including bone mar-
row and liver, at the therapeutic doses. The 
authors suggested that introduction of curcum-
in into traditional chemotherapy regimens is a 
most promising way to counter the spread of 
non-small cell lung cancer [132]. Cort et al. 
found that concurrent use of curcumin with 
bleomycin induced extensive expression of cas-
pase-3, -8 and -9 in human NTera-2 neural 
cells, greater than either drug alone. They sug-
gested that the effects of curcumin and bleo-
mycin on apoptotic signaling pathways are syn-
ergistic and proposed combination regimens to 
decrease therapeutic dose and side effects 
[133]. Duan et al. observed that simultaneous 
administration of doxorubicin and curcumin 
achieved the highest reversal efficacy and 
downregulation of P-glycoprotein in MCF-7/
ADR, an MCF-7 breast cancer cell line resistant 
to doxorubicin [134].
In a combination regimen, curcumin potentiat-
ed the therapeutic efficacy of bortezomib in 
multiple myeloma, as evidenced by inhibition of 
IL-6/sIL-6R–induced STAT3 and ERK phosphor-
ylation, and synergistically inhibited the growth 
of multiple myeloma cells co-cultured with bone 
marrow stromal cells [135]. Mujtaba et al. 
found therapeutic benefit when a water-soluble 
analog of curcumin enhanced the proteasome-
inhibitory effect of bortezomib in multiple 
myeloma cells. The sensitivity of the myeloma 
cells to cytotoxic killing in the presence of oth-
erwise sublethal concentrations of bortezomib 
was enhanced by incubation with the curcumin 
analog [136].
Bava et al. observed that curcumin increased 
sensitivity of tumor cells more efficiently to the 
therapeutic effect of paclitaxel, as evidenced 
by increased cytotoxicity and reduced DNA syn-
thesis, activation of caspases, and cytochrome 
c release in HeLa cells. Evaluation of signaling 
pathways common to both drugs revealed that 
this synergism was due to downregulation of 
NF-κB and serine/threonine kinase Akt path-
ways. The investigators concluded that pacli-
taxel in combination with curcumin may provide 
a superior therapeutic index and advantage in 
the clinic for the treatment of refractory tumors 
[137]. In their investigation, Kang et al. looked 
into whether inactivation of NF-κB by curcumin 
would enhance the efficacy of paclitaxel for 
inhibiting breast cancer growth in vitro and in 
vivo. They confirmed that curcumin inhibited 
paclitaxel-induced activation of NF-κB and 
potentiated the growth-inhibitory effect of 
paclitaxel in MDA-MB-231 breast cancer cells. 
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The combination of curcumin with paclitaxel 
elicited significantly greater inhibition of cell 
growth and more apoptosis than either agent 
alone. In the experimental MDA-MB-231 breast 
cancer murine model, combination therapy 
with paclitaxel and curcumin significantly 
reduced tumor size and decreased tumor cell 
proliferation, increased apoptosis, and decrea- 
sed the expression of MMP-9 compared with 
either agent alone [138].
Conclusion 
Cancer is not one disease but a combination of 
many; to effectively halt tumor progression, a 
drug that can target multiple dysregulated pro-
teins would be ideal. Targeted therapies have 
their limitations, the most prominent being that 
cancer cells develop resistance to them. In 
some patients whose cancer develops resis-
tance to imatinib, for example, a mutation in 
the BCR-ABL gene has changed the protein so 
that it no longer can bind to this drug. In most 
such cases, another targeted therapy that 
could overcome this resistance is not available. 
Combinations of targeted therapies with either 
other targeted therapies or more traditional 
therapies may be the solution to this problem. 
Curcumin, a natural polyphenol, appears to 
possess a blend of anticarcinogenic, proapop-
totic, antiangiogenic, antimetastatic, immuno-
modulatory, and antioxidant activities. The 
molecular mechanisms underlying the pleo-
tropic activities of curcumin are diverse and 
involve combinations of cell signaling pathways 
at multiple levels of tumorigenesis. With the 
ongoing problems of drug resistance, toxicity, 
and high treatment cost associated with the 
current FDA-approved anticancer drugs (Table 
1), it would be most advantageous to look into 
curcumin as an anticancer agent, to be admin-
istered alone or in combination with available 
anticancer drugs; such explorations may dem-
onstrate that curcumin offers not only efficacy 
but also affordability. 
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